-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Spine Stereotactic Radiosurgery: A Critical Evaluation of the Evidence to Guide Clinical Practice
Spine metastases represent a common complication of lung cancer and other cancers, with approximately 40% of patients developing clinically significant spinal metastatic disease and up to 90% developing subclinical micrometastases. In addition to site-associated pain, spine metastases can also cause neurologic deficits, reduced mobility, and a decline in a patient’s performance status and quality of…
-
Treatment of Immunotherapy-Related Ophthalmic Toxicities: An Interview With Dr. Asim V. Farooq
Ophthalmologists are beginning to identify common adverse side effects seen in patients with cancer receiving immunotherapy. The IASLC Lung Cancer News spoke with Asim V. Farooq, MD, about how best to care for patients experiencing or susceptible to such toxicities. Dr. Farooq is associate professor of Ophthalmology and Visual Science at The University of Chicago.
-
Ticiana Leal, MD, Moves to Emory University School of Medicine
Ticiana Leal, MD, has moved to Emory University School of Medicine as associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology. Dr. Leal’s clinical research focuses on clinical trials of chemotherapy and/or immunotherapy agents to treat cancers of the lung. Dr. Leal has authored or coauthored…
-
Balancing the Benefits and Harms of Lung Cancer Screening
In the National Lung Screening Trial, screening with 2 years of annual low-dose computed tomography (LDCT) achieved a 20% decrease in lung cancer mortality in high-risk populations when compared with chest radiography. A decade later, in March 2021, the U.S. Preventive Services Task Force (USPSTF) expanded the eligibility for U.S. adults to ages 50 to…
-
The eNRGy1 Global Multicenter Registry: NRG1 Fusions as a Hidden Target in Lung Cancer
Gene fusions involving ALK, ROS1, RET, and NTRK are now established targets in NSCLC, for which highly effective and well-tolerated kinase inhibitors are the preferred initial therapy. A growing body of evidence suggests fusions in NRG1 (neuregulin 1) will emerge as yet another relevant genomic target. NRG1 fusions are rare events, present across tumor types…
-
Adoption of VATS Continues to Vary Globally
Surgical resection remains the gold standard for patients diagnosed with early-stage lung cancer, and since the early 1990s, video-assisted thoracoscopic surgery (VATS) lobectomy has been acknowledged as an effective – and preferred — minimally invasive approach for lung cancer surgery. However, VATS requires specialized training and equipment meaning adoption of this technique has not been…
-
First New Second-line Therapy for SCLC in Australia in 20 Years
SEPTEMBER 14, 2021—Lurbinectedin received approval from the Therapeutic Goods Administration (TGA) as treatment for patients with metastatic SCLC who experienced disease progression during or after receipt of platinum-based chemotherapy. The TGA collaborated with the U.S. Food and Drug Administration (FDA) through Project Orbis to accelerate Australian approval under a provisional regulatory pathway. Approval was based…
-
Sotorasib Scores Second-line Approval in Canada
SEPTEMBER 14, 2021—Health Canada approved sotorasib for second-line treatment of patients with locally advanced or metastatic NSCLC and a KRAS G12C mutation. A Notice of Compliance with Conditions was granted based on the overall response rate and duration of response found in the phase II CodeBreak 100 trial. Continued approval is contingent on verification and…
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
Mario Lacouture, MD, is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center and specializes in the dermatologic side effects of cancer treatment. He is the founder of the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary program bringing together patient care, education, and research, and is…
-
Question Literature’s Face Value
Not all published papers are on equal footing.